Livagen
Lung Bioregulatory Peptide
Livagen is a short peptide bioregulator derived from the thymus and is known for its ability to modulate gene expression, enhance immune function, and support cellular repair processes. Originally developed in Russia, Livagen is classified as a geroprotective peptide, meaning it plays a role in slowing down age-related degenerative changes at the cellular level. It works by regulating DNA transcription, particularly affecting genes involved in immune response, oxidative stress resistance, and protein synthesis.
Livagen has shown potential in improving immune system function, enhancing cognitive performance, and supporting liver detoxification. It has also been investigated for its role in promoting longevity, improving sleep quality, and modulating inflammation. Due to its ability to restore cellular homeostasis, it is often used in anti-ageing protocols, neuroprotection, and chronic disease management.
Protocols
1. Anti-Ageing & Longevity
Dosage: 10–20 mcg per injection, once daily
Cycle: 10–20 days, repeated every 3–6 months
Administration: Subcutaneous (SC) or intramuscular (IM) injection, preferably in the evening
Stacking: Often combined with Epitalon or Thymalin for enhanced regenerative effects
Expected Benefits: Improved cellular repair, reduced oxidative stress, enhanced DNA stability
2. Immune System Modulation
Dosage: 10–20 mcg per injection, once daily
Cycle: 10–15 days, with breaks as needed
Administration: SC or IM injection
Stacking: Can be combined with Thymosin Alpha-1 for stronger immune support
Expected Benefits: Enhanced immune response, reduced inflammation, improved resistance to infections
3. Cognitive Function & Neuroprotection
Dosage: 10–20 mcg per injection, once daily
Cycle: 10–20 days, repeated 2–3 times per year
Administration: SC injection, preferably at night
Stacking: Works well with Semax and Cerebrolysin for cognitive enhancement
Expected Benefits: Improved memory, neuroprotection, enhanced mental clarity
4. Liver Detoxification & Support
Dosage: 10–20 mcg per injection, once daily
Cycle: 10–20 days, repeated as needed
Administration: SC or IM injection
Stacking: Can be combined with Glutathione for liver detox support
Expected Benefits: Enhanced liver function, improved detoxification, reduced oxidative damage
Further reading
Livagen operates by influencing gene expression at the epigenetic level, restoring normal function to cells affected by ageing or stress. Studies have shown that it can upregulate protective genes while suppressing those involved in degenerative processes. This makes it particularly useful in combating age-related decline, immune dysfunction, and chronic diseases.
One of its key benefits is its role in regulating the immune system. By modulating cytokine production and enhancing T-cell function, Livagen has been found to improve immune resilience in both healthy individuals and those with compromised immune function. It also appears to have anti-inflammatory properties, making it potentially useful in autoimmune conditions.
Research into Livagen’s effects on the nervous system suggests that it may enhance synaptic plasticity, reduce neuroinflammation, and improve neurotransmitter balance. This has led to interest in its potential applications for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Additionally, its impact on melatonin regulation may contribute to improved sleep quality, further supporting cognitive and systemic health.
Despite its promising benefits, Livagen remains relatively under-researched outside of Russia, where most clinical studies have been conducted. While it has been deemed safe for use in various trials, further research is needed to fully understand its mechanisms and long-term effects.
References
- Khavinson, V. K., & Tarnovskaya, S. I. (2001). "Peptide bioregulators and ageing: Mechanisms of action and prospects for clinical application." Biogerontology, 2(2), 97–105.
Anisimov, V. N., et al. (2011). "Effect of peptide bioregulators on life span and tumour incidence in rats." Mechanisms of Ageing and Development, 132(3), 137–143.
Morozov, V. G., et al. (2009). "The effect of short peptides on immune system function in elderly individuals." Immunology Letters, 123(2), 151–155.
Khavinson, V. K., et al. (2016). "Short peptides regulate gene expression and protein synthesis in ageing." Aging Research Reviews, 30, 39–52.
Alimova, I. N., & Khavinson, V. K. (2018). "Neuroprotective effects of peptide bioregulators: Potential applications in neurodegenerative diseases." Neuroscience & Behavioral Physiology, 48(5), 590–597.